Impact of antibiotic resistance on the treatment of gram-negative sepsis

被引：4

作者：

Baden L.R. ^{[1
]}

Eisenstein B.I. ^{[2
]}

机构：

[1] Division of Infectious Disease, Brigham and Women’s Hospital, and Harvard Medical School, PBB-A4, 15 Francis Street, Boston, 02115, MA

[2] Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, 02115, MA

来源：

Current Infectious Disease Reports | 2000年 / 2卷 / 5期

关键词：

Diagn Microbiol Infect; Lactam; National Nosocomial Infection Surveillance; National Nosocomial Infection Surveillance System; Resistant Organism;

D O I：

10.1007/s11908-000-0067-z

中图分类号：

学科分类号：

摘要：

Resistance among gram-negative organisms has greatly complicated the care of the septic patient. An understanding of the likely source of infection, the epidemiologic risk of the patient being exposed to an antibiotic-resistant organism, and the specific vulnerabilities of the host are essential to the proper selection of empiric antimicrobial therapy. In this report, we discuss the epidemiology, antibiotic resistance mechanisms, microbiology, treatment strategies, and diagnostic and therapeutic innovations in the approach to the septic patient. © 2000, Current Science Inc.

引用

页码：409 / 416

页数：7

共 43 条

[11]

Fridkin S.K., Steward C.D., Edwards J.R., Et al., Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals, Clin Infect Dis, 29, pp. 245-252, (1999)

[12]

Yinnon A.M., Butnaru A., Raveh D., Et al., Klebsiella bacteraemia: community versus nosocomial infection, QJM, 89, pp. 933-941, (1996)

[13]

Emori T.G., Culver D.H., Horan T.C., Et al., National nosocomial infections surveillance system (NNIS): description of surveillance methods, Am J Infect Control, 19, pp. 19-35, (1991)

[14]

Vincent J.L., Bihari D.J., Suter P.M., Et al., The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study, EPIC International Advisory Committee JAMA, 274, pp. 639-644, (1995)

[15]

Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P., Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System, Am J Cardiol, 82, pp. 789-793, (1998)

[16]

Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P., Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System, Crit Care Med, 27, pp. 887-892, (1999)

[17]

Fridkin S.K., Welbel S.F., Weinstein R.A., Magnitude and prevention of nosocomial infections in the intensive care unit, Infect Dis Clin North Am, 11, pp. 479-496, (1997)

[18]

Miller G.H., Sabatelli F.J., Hare R.S., Et al., The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups, Clin Infect Dis, 24, pp. S46-S62, (1997)

[19]

Dornbusch K., King A., Legakis N., Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR), Scand J Infect Dis, 30, pp. 281-288, (1998)

[20]

Barsic B., Beus I., Marton E., Et al., Antibiotic resistance among gram-negative nosocomial pathogens in the intensive care unit: results of 6-year body-site monitoring, Clin Ther, 19, pp. 691-700, (1997)

← 1 2 3 4 5 →